Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab

  • STATUS
    Recruiting
  • participants needed
    36
  • sponsor
    University Hospital, Tours
Updated on 14 August 2022
lymphoma
pneumovax
vaccination
immunosuppression
diffuse large b-cell lymphoma
r-chop
anti-cd20 monoclonal antibody
prevnar
polysaccharide
conjugate vaccine

Summary

Pneumococcal infections remain frequent and potentially fatal. To prevent them, two anti-pneumococcal vaccines exist: a 13-valent conjugate vaccine (Prevenar) and a 23-valent polysaccharide vaccine (Pneumovax). For their utilization, several studies approved a prime-boost strategy. It consist two administer Pneumovax at least two months later than Prevenar. Patients with diffuse large B-cell Lymphoma (DLBCL) have a higher-risk to develop a pneumococcal infection. The main reason is immunosuppression, induced by rituximab (B cell depletion), chemotherapy and lymphoma. Patients are treated by immunochemotherapy, combining rituximab (anti-CD20 monoclonal antibody) and conventional chemotherapy (CHOP). However, those patients have a low rate of vaccination (about 15%).

Description

Pneumococcal infections remain frequent and potentially fatal. To prevent them, two anti-pneumococcal vaccines exist: a 13-valent conjugate vaccine (Prevenar) and a 23-valent polysaccharide vaccine (Pneumovax). For their utilization, several studies approved a prime-boost strategy. It consist two administer Pneumovax at least two months later than Prevenar. Patients with diffuse large B-cell Lymphoma (DLBCL) have a higher-risk to develop a pneumococcal infection. The main reason is immunosuppression, induced by rituximab (B cell depletion), chemotherapy and lymphoma. Patients are treated by immunochemotherapy, combining rituximab (anti-CD20 monoclonal antibody) and conventional chemotherapy (CHOP). However, those patients have a low rate of vaccination (about 15%). Also, in the current literature, rare studies investigated prime-boost immunogenicity in this relevant population. The investigators will evaluate vaccinal response of 10 serotype-specific immunoglobulin G (1, 3, 4, 6B, 7F, 9V, 14, 18C, 19F, 23F) at different time of treatment.

The investigators search to compare efficiency of prime-boost anti-pneumococcal vaccination according to the time of prevenar administration (before or after immunochemotherapy) and to the dose of Prevenar (single or double-dose).

Details
Condition Pneumococcal infection, pneumococcal infections, Pneumococcal Disease, Diffuse Large B-Cell Lymphoma, streptococcus pneumoniae infections
Treatment Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma
Clinical Study IdentifierNCT04214444
SponsorUniversity Hospital, Tours
Last Modified on14 August 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note